Kinemed and CHDI Expand Huntington’s Disease Partnership

Kinemed, an Emeryville, CA-based biotechnology company, has expanded its partnership with the CHDI Foundation, a non-profit research organization focused exclusively on accelerating therapy development for Huntington’s disease (HD). The initial collaboration leveraged Kinemed’s platform for analyzing microtubule dynamics to identify disease biomarkers in the cerebrospinal fluid (CSF) of HD models. The extension aims to identify pharmacodynamic biomarkers that can be used in clinical trials by combining biomarker studies with therapeutic interventions. Kinemed has already explored applications of this technology for ALS: In 2007, Kinemed was one of the winners of the Prize4Life ‘thought’ prizes of the $1M ALS Biomarker Prize. Hopefully we will see the company expands its current biomarker discovery efforts into the field of ALS!

Kinemed, an Emeryville, CA-based biotechnology company, has expanded its partnership with the CHDI Foundation, a non-profit research organization focused exclusively on accelerating therapy development for Huntington’s disease (HD). The initial collaboration leveraged Kinemed’s platform for analyzing microtubule dynamics to identify disease biomarkers in the cerebrospinal fluid (CSF) of HD models. The extension aims to identify pharmacodynamic biomarkers that can be used in clinical trials by combining biomarker studies with therapeutic interventions. Kinemed has already explored applications of this technology for ALS: In 2007, Kinemed was one of the winners of the Prize4Life ‘thought’ prizes of the $1M ALS Biomarker Prize. Hopefully we will see the company expands its current biomarker discovery efforts into the field of ALS!

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail